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R AD I A T I ON ONCO LOG Y PH Y S I C S
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Abstract
Purpose/Objectives: To retrospectively evaluate the plan quality, treatment effi-
ciency, and accuracy of volumetric modulated arc therapy (VMAT) plans for thoracic
spine metastases using stereotactic body radiotherapy (SBRT).
Materials/Methods: Seven patients with thoracic vertebral metastases treated with
noncoplanar hybrid arcs (NCHA) (1 to 2 3D-conformal partial arcs +7 to 9 IMRT
beams) were re-optimized with VMAT plans using three coplanar arcs. Tumors were
located between T2 and T7 and PTVs ranged between 24.3 and 240.1 cc (median
48.1 cc). All prescriptions were 30 Gy in 5 fractions with 6 MV beams treated using
the Novalis Tx linac equipped with high definition multileaf collimators (HDMLC).
MR images were fused with planning CTs for target and OAR contouring. Plans
were compared for target coverage using conformality index (CI), homogeneity
index (HI), D90, D98, D2, and Dmedian. Normal tissue sparing was evaluated by
comparing doses to the spinal cord (Dmax, D0.35, and D1.2 cc), esophagus (Dmax
and D5 cc), heart (Dmax, D15 cc), and lung (V5 and V10). Data analysis was per-
formed with a two-sided t-test for each set of parameters. Dose delivery efficiency
and accuracy of each VMAT plan was assessed via quality assurance (QA) using a
MapCHECK device. The Beam-on time (BOT) was recorded, and a gamma index
was used to compare dose agreement between the planned and measured doses.
Results: VMAT plans resulted in improved CI (1.02 vs. 1.36, P = 0.05), HI (0.14 vs.
0.27, P = 0.01), D98 (28.4 vs. 26.8 Gy, P = 0.03), D2 (32.9 vs. 36.0 Gy, P = 0.02),
and Dmedian (31.4 vs. 33.7 Gy, P = 0.01). D90 was improved but not statistically
significant (30.4 vs. 31.0 Gy, P = 0.38). VMAT plans showed statistically significant
improvements in normal tissue sparing: Esophagus Dmax (22.5 vs. 27.0 Gy,
P = 0.03), Esophagus 5 cc (17.6 vs. 21.5 Gy, P = 0.02), and Heart Dmax (13.1 vs.
15.8 Gy, P = 0.03). Improvements were also observed in spinal cord and lung spar-
ing as well but were not statistically significant. The BOT showed significant reduc-
tion for VMAT, 4.7  0.6 min vs. 7.1  1 min for NCHA (not accounting for couch
kicks). VMAT plans demonstrated an accurate dose delivery of 95.5  1.0% for clin-
ical gamma passing rate of 3%/3 mm criteria, which was similar to NCHA plans.
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Conclusions: VMAT plans have shown improved dose distributions and normal tis-
sue sparing compared to NCHA plans. Significant reductions in treatment time could
potentially minimize patient discomfort and intrafraction movement errors. VMAT
planning for SBRT is an attractive option for the treatment of metastases to tho-
racic vertebrae, and further investigation using alternative fractionation schedules is
warranted.
P A C S
2017-00784A
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1 | INTRODUCTION
The spinal vertebrae are a common site of metastasis for many can-
cers and can cause significant pain and neurologic dysfunction.1 Each
year, nearly 20,000 new cases of spinal metastases are diagnosed in
North America with an annual prevalence of around 100,000
cases.2–4 Bone metastases are common in many different solid
tumors with up to 90 percent of patients with breast or prostate
cancer having osseous disease in autopsy studies.5,6 Pathologic frac-
tures in the spine from metastases are painful and debilitating result-
ing in poor quality of life, which is an important consideration in the
setting of recent life-prolonging advances in systemic treatment for
metastatic disease.7–10 For these reasons, palliative local manage-
ment will play an ever more crucial role in the treatment of meta-
static cancer involving the spine.
Randomized data support the combination of surgery and radia-
tion in cases of spinal cord compression; however, the optimal man-
agement for spinal metastases without cord compression is still
unclear.11 Radiation offers the advantage of sparing the patient from
an invasive procedure, but conventional techniques are limited by
the tolerance dose of the spinal cord.12 Conventional single fraction
treatments (BED ~14 Gy10) and multifraction treatments (BED ~30–
40 Gy10) have demonstrated low clinical complete response rates
and suboptimal tumor control. Retreatment is often required, espe-
cially for single fraction treatments, and may be precluded by prior
radiation leaving surgery as the only option.13–16
SBRT has emerged as an attractive method of dose escalation
(BED ~40–80 Gy10) while respecting spinal cord tolerance through
advanced planning techniques using image-guided (IG) intensity-
modulated radiation therapy (IMRT).17–21 SBRT can be delivered
on multiple platforms with IMRT including multileaf collimator
(MLC) equipped on most treatment units, TomoTherapy, or Cyber-
Knife. Delivery of SBRT to the vertebrae while avoiding the spinal
cord typically requires the generation of complex hybrid plans
consisting of noncoplanar partial arcs and static IMRT beams.
While these methods produce highly conformal plans with a
higher BED and shorter overall treatment time as compared to
traditional two-dimensional palliative dose regimens, the individual
treatments are lengthy and require a large number of total moni-
tor units.22
Methodology to minimize BOT is an area of interest for SBRT to
the spine due to concerns over intrafraction motion and patient
comfort. Volumetric Modulated Arc Therapy (VMAT) is an elegant
technique of delivering IMRT that allows for shorter treatment times
achieved by optimizing MLC positions and dose rate while the gan-
try rotates around the patient with the beam-on.23–25 SBRT to the
spine has been demonstrated to be feasible and safe in a phase I
study; however, concerns over the possibility of vertebral compres-
sion fracture and radiation-induced myelitis remain and are an active
area of investigation.26–28 Techniques for planning and immobiliza-
tion are of special interest in regards to limiting toxicity by keeping
treatment times and intrafraction motion to a minimum.29,30 In this
report, we retrospectively evaluate VMAT plans for thoracic spinal
metastases using SBRT in terms of plan quality, treatment efficiency,
and accuracy.
2 | MATERIALS AND METHODS
2.A | Hybrid planning and treatment procedure
For this retrospective study, we replanned seven patients in the
Eclipse version 11.0 treatment planning system (Varian, Palo Alto,
CA, USA). These patients were previously treated at our institution
for thoracic vertebral metastases with SBRT using iPlan (BrainLAB,
Feldkirchen, Germany). CT simulations were performed on a 16
slice Phillips Brilliance Big Bore CT Scanner. Highly conformal SBRT
treatment plans were generated using noncoplanar hybrid arcs (a
combination of 3D noncoplanar conformal arcs and nonopposing
static beams). Treatments were delivered with a Novalis TX linear
accelerator (Varian, Palo Alto, CA, USA) using 6 MV beams
(600 MU/min) and a HDMLC. The HDMLC on this machine con-
sisted of 120 leaves (30 pairs of 2.5 mm leaves surrounded by 30
pairs of 5 mm leaves). No additional margin for dose buildup was
applied at the edges of the MLC blocks beyond the PTV. All
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treatment plans were calculated using the pencil-beam algorithm
with heterogeneity corrections turned on with 2.0 9 2.0 9 2.0
mm3 dose grid sizes. A Monte Carlo algorithm is also available and
is used for lung SBRT treatments in our clinic; however, based on
clinical experience there are no significant differences with the
Monte Carlo algorithm for spinal SBRT, and the pencil-beam algo-
rithm is standardly used for these treatments. The treatment pre-
scription was 30 Gy in 5 fractions with at least 90% of the PTV
encompassing 100% of the prescription isodose. Immobilization was
accomplished with a BodyFIX double-vacuum immobilization device
(Elekta, Stockholm, Sweden) and abdominal compression. The
ExacTrac system from BrainLAB was utilized for initial patient
setup. Quality assurance checks were performed daily in order to
ensure accurate target localization. Prior to each treatment, a pair
of oblique kV x-ray images was acquired and automatic 2D/3D
image registration was performed in the ExacTrac system. Cone
beam CT scans were then performed with Varian onboard imaging
(OBI). All quality assurance procedures were in compliance with the
standard SBRT treatment delivery technique following AAPM
guidelines.27,28 Specifically, the Winston-Lutz test was performed
daily before SBRT treatments confirming coincidence of the radia-
tion isocenter and mechanical isocenter.31
F I G . 1 . Comparison of isodose
distributions and the DVHs for NC-HA
(left) and RapidArc (right) VMAT planning
in the same case shown in axial, coronal,
and sagittal views. Planning target volume
(PTV) is shown in orange and partial-spinal
cord in yellow. Isodose lines are shown as
colorwash (30 Gy, orange; 28.5 Gy green;
21 Gy light-blue and 15 Gy dark-blue). The
other critical structures such as esophagus,
heart and lung contours are also shown in
the 3D image views. [Correction added on
8th February 2018, after first online
publication: Caption was corrected.]
56 | MALLORY ET AL.
2.B | VMAT planning
After obtaining institutional review board approval from our institu-
tion, all DICOM 3D-CT datasets and contoured structures for the
seven treated patients were electronically transferred from BrainLAB
iPlan workstation to Eclipse treatment planning system for the
purpose of replanning and optimization using the VMAT technique.
All VMAT plans were generated for use with a 6 MV beam on a
Novalis TX linear accelerator equipped with HDMLCs (2.5 mm leaf
width at isocenter) with a maximum dose rate of 600 MU/min. The
isocenter was placed at the center of the PTV in the beam’s eye
view. Three full coplanar arcs covered 358° gantry rotation. The first
clockwise arc used a 25° collimator rotation, and the counter clock-
wise arc used a complementary 335° rotation. The second clockwise
arc used 55° collimator rotation to reduce the overlapping MLC ton-
gue-and-groove leakage for VMAT plans. All treatment plans were
generated in Eclipse TPS using anisotropic analytical algorithm (AAA)
for heterogeneity corrections with 2.0 9 2.0 9 2.0 mm3 dose grid
sizes for dose calculations. Each plan had a dose delivery schema of
30 Gy in 5 fractions with at least 90% of the PTV receiving the
prescription dose (D90% ≥30 Gy). Gantry speed, dose rate, and
MLC motion were optimized in VMAT plans using the inverse
optimization algorithm in the Eclipse TPS to achieve desired dose
distributions.
2.C | Evaluation of dose distribution
Dose volume histograms were generated for all hybrid and VMAT
treatment plans in the Eclipse TPS for the PTV, spinal cord, esopha-
gus, and heart. Dosimetric evaluation of these plans was performed
by calculating conformality index (CI) and heterogeneity index (HI)
using the DVH of the PTV.
The CI as defined per ICRU is:
CI ¼
Vip
Vðt arg etÞ
(1)
where Vip represents the treated volume enclosed by the prescrip-
tion isodose line and V(target) represents the target volume for the
PTV. CI values near unity indicate superior plan conformity of dose
distribution to the target volume.
F I G . 2 . Comparison DVHs for NC-HA
and RapidArc VMAT planning in the same
case shown in axial, coronal, and sagittal
views. The DVHs NC-HA (square) and
RapidArc VMAT (triangle) clearly shows
significant dosimetric advantages when
using VMAT planning for thoracic vertebral
SBRT. Contours and corresponding DVHs
represented: PTV (orange), heart (dark-
blue), esophagus (dark-green), spinal cord
(yellow), and lung (light-blue). [Correction
added on 8th February 2018, after first
online publication: Caption was corrected.]
F I G . 3 . Experimental QA setup in treatment room showing the
MapCHECK QA device inserted in the middle of plastic phantom.
[Correction added on 8th February 2018, after first online
publication: Caption was corrected.]
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The HI as defined per ICRU is:
HI ¼
D2%  D98%ð Þ
Dmedian
(2)
where D2% and D98% correspond to the dose delivered to 2% and
98% of the PTV, respectively, and Dmedian represents the median
dose to the PTV. Smaller values of HI indicate better dose homo-
geneity within the target volume.
Each hybrid and VMAT plan was evaluated for PTV coverage
and dose to the OARs (spinal cord, esophagus, and heart).
2.D | Efficiency and dose delivery accuracy
The dose delivery efficiency of each plan was evaluated in terms of
total number of MUs and actual BOT, which was recorded at the
treatment console while delivering the QA plan. Delivery accuracy of
the QA plan was assessed by physically measuring the 2D dose dis-
tribution of each plan on an in-house static plastic phantom which
housed the MapCHECK device (Sun Nuclear Corporation.; Mel-
bourne, FL, USA). The plastic phantom was made up of
30 9 30 9 20 cm3 in dimensions provided buildup of 10 cm at the
top and bottom as well as 5 cm on all other sides. All QA plans were
delivered at the machine in one session, minimizing dependence of
the QA passing rates on machine output. The measured cumulative
2D dose plane computed by the Eclipse treatment planning system
(version 11.0) was compared with the measured dose using the
MapCHECK QA device inserted in the middle of plastic phantom as
shown in Fig. 1. Upon completion of delivered dose, data were ana-
lyzed with MapCHECK software (SNC patient, version 6.1) using the
Van Dyk gamma passing rate criteria of 3/3 (3%/3 mm).
3 | RESULTS
Computed dose distributions for both hybrid (Hyb) and VMAT
(Rapid) plans in coronal, sagittal, and axial views for one representa-
tive patient are shown in Fig. 2. The corresponding DVHs for both
plans of the same patient are also shown in Fig. 3.
Table 1 presents the dosimetric results of all seven hybrid and
VMAT plans. VMAT plans demonstrated excellent conformality
reflecting improvement in the conformality index from a mean value
of 1.36  0.40 for hybrid plans to 1.02  0.04 for VMAT plans
(P = 0.05). Dose homogeneity also improved, evidenced by D2 and
D98 values closer to prescription dose, which resulted in the tight-
ening of the homogeneity index from 0.27  0.09 for hybrid plans
to 0.14  0.05 for VMAT plans (P = 0.01). PTVD90 was improved
for VMAT plans, although not to a statistically significant level
(30.4  0.3 vs. 31.0  0.2 Gy, P = 0.38).
Tables 2 and 3 present the dosimetric data for the organs at risk
(OARs) for hybrid and VMAT plans, respectively. Maximum doses to
the spinal cord, esophagus, and heart are shown along with D0.3 and
D1.2 cc for the spinal cord, D5 cc for the esophagus, and D15 cc for
the heart. The volume of the lung receiving no more than 5 and 10 GyT
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is shown along with the minimum dose to the hottest 1000 cc of lung
(D1000 cc) as an indicator of low dose spread. For VMAT plans com-
pared to hybrid plans, the average maximum dose to the esophagus
improved from 27.0 to 22.5 Gy (P = 0.03), and the average maximum
dose to heart improved from 15.8 to 13.1 Gy (P = 0.03). Similarly,
average esophagus dose to 5 cc volume improved from 21.5 to
17.6 Gy (P = 0.02). There was a trend for improvement in spinal cord
and lung sparing, but these findings were not statistically significant.
The average cord max was 19.9 Gy for hybrid plans and 17.8 Gy for
VMAT plans (P = 0.16). The average lung V5 was 19.2 for hybrid plans
and 18.5 Gy for VMAT plans (P = 0.42).
Table 4 shows detailed information on total number of MUs,
BOT, and QA passing rate values for hybrid and VMAT plans. Data
are presented as the mean and standard deviations for all seven
patients. For VMAT plans, the total number of MUs was
2598  345 on average compared to 3542  495 for hybrid plans
(P = 0.003). This reduction in MUs translated into lower BOTs from
an average of 7.1  1.0 min to 4.7  0.6 min (P < 0.001).
4 | DISCUSSION
In this study, we have presented a dosimetric comparison of two
methods of delivering SBRT for thoracic vertebral metastases: (a)
noncoplanar hybrid arcs consisting of 1-2 partial arcs and 7-9 static
IMRT beams and (b) VMAT with three full coplanar arcs. We found
that VMAT plans provided improved dose distributions and
improved normal tissue sparing with statistically significant improve-
ments in heart and esophagus doses. VMAT plans were twice as
homogeneous as hybrid plans as indicated by the homogeneity index
(0.14 vs. 0.27, P = 0.01).
Homogeneous dose delivery is especially important in SBRT
treatment of the thoracic spine due to the proximity of the spinal
cord to the vertebral bodies, unlike in lung SBRT where
TA B L E 2 Dose to organs at risk for hybrid plans for all seven patients.
Patient
no
Hybrid plan
Cord
max (Gy)
Cord 0.3
cc (Gy)
Cord 1.2
cc (Gy)
Esophagus
max (Gy)
Esophagus
5 cc (Gy)
Heart
max (Gy)
Heart
15 cc (Gy)
Lung
V5 (cc)
Lung
V10 (cc)
Lung D1000
cc (cGy)
I 11.9 10.4 6.5 13.3 8.6 14.1 7.9 10.1 2.9 78
II 21.2 20.3 19.3 30.7 25.3 4.4 5.4 6.7 2.7 22
III 34.3 23.2 22.4 32.8 29.3 21.4 10.9 53.1 18.6 735
IV 15.0 12.8 12.0 20.2 15.8 12.7 3.5 7.8 2.5 89
V 18.5 15.7 14.7 32.2 26.8 27.8 6.7 19.6 1.2 258
VI 15.0 14.0 12.5 27.5 21.6 16.4 5.2 15.3 2.6 130
VII 23.5 22.1 21.4 32.1 23.0 14.0 4.2 21.8 3.2 57
Mean 19.9  7.5 16.9  5.0 15.5  5.8 27.0  7.5 21.5  7.1 15.8  7.3 5.6  3.3 19.2  16.0 4.8  6.1 195.6  249.6
TA B L E 3 Dose to organs at risk for VMAT plans for all seven patients.
Patient
no
VMAT plan
Cord
max (Gy)
Cord 0.3
cc (Gy)
Cord 1.2
cc (Gy)
Esophagus
max (Gy)
Esophagus
5 cc (Gy)
Heart
max (Gy)
Heart
15 cc (Gy)
Lung
V5 (cc)
Lung
V10 (cc)
Lung D1000
cc (cGy)
I 11.7 10.3 6.7 12.9 7.4 10.8 6.7 10.7 2.8 71
II 21.0 19.4 17.0 25.4 20.0 2.1 5.2 6.9 2.8 19
III 24.3 23.1 22.3 32.8 29.3 21.4 10.9 52.8 18.8 729
IV 14.8 12.7 11.8 19.9 15.1 12.5 2.6 7.1 1.8 50
V 16.8 14.1 13.4 26.4 21.8 20.9 6.7 21.8 1.1 146
VI 14.4 12.9 12.6 18.5 14.4 11.8 4.4 12.2 1.3 80
VII 21.6 17.8 15.3 21.9 15.6 12.2 3.9 18.2 2.7 56
Mean 17.8  4.6 15.7  4.5 14.2  4.8 22.5  36.4 17.7  6.9 13.1  6.6 5.1  3.4 18.5  16.1 4.5  6.4 164.4  252.0
TA B L E 4 Detailed information on average total number of MUs,
beam-on time, and IMAT QA pass rate values for Hybrid and VMAT
plans.
Patient no
Hybrid plan VMAT plan
Monitor
units
Beam-on
time (min)
Monitor
units
Beam-on
time (min)
I 4152 8.30 3216 5.63
II 3123 6.25 2651 4.84
III 2739 5.48 2437 4.27
IV 3949 7.90 2145 3.76
V 3353 6.71 2635 4.81
VI 3756 7.51 2297 4.19
VII 3720 7.44 2808 5.12
Mean 3542  495 7.08  0.99 2598  354 4.66  0.63
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heterogeneous dose is desired. Less homogeneous plans will have
more variation between hot and cold spots. Due to setup uncertain-
ties, such heterogeneous plans with multiple hot spots in the vicinity
of the spinal cord are undesirable because intrafraction (patient
motion) and interfraction (daily setup errors) variation may result in
an adjacent hot spot on the spinal cord. Because of this uncertainty
and threat of overdosing the spinal cord, most physicians will opt for
fractionated treatment instead of single fraction treatment. We have
previously published on the use of single fraction stereotactic body
radiosurgery (SBRS) to the spine using VMAT and demonstrated that
such treatment was feasible following RTOG 0631 dosimetric criteria
with compliant spinal cord doses and highly conformal and homoge-
neous dose distributions.32,33 However, there remain a number of
concerns regarding single fraction treatment in regard to normal tis-
sue dosing and treatment logistics.
Esophageal dose has been demonstrated to be particularly prob-
lematic for single fraction treatments.34,35 Cox et al. studied SBRS
treatment in 182 patients with tumors abutting the esophagus and
found a 6.8% rate of acute or late grade 3 + esophageal toxicity.
The median dose in this study was 24 Gy, and the median follow-up
time was 12 months. A dose–response model was generated, which
revealed sharply increasing rates of toxicity when the dose to the
hottest 2.5 cc of the esophagus (D2.5 cc) was greater than 14 Gy.
Under 14 Gy, the risk of grade 3 + toxicity was <5%, but this risk
increased to 15% at a D2.5 cc of 20 Gy.34 The esophageal dose
constraints on the RTOG 0631 protocol were D0.3 cc < 18 Gy, and
D5 cc < 11.9 Gy.33 In our single fraction study, the maximum dose
to the esophagus was 11.2 Gy on average (range 7.1–14.9 Gy),
which was well below the protocol requirement.32 In the current
study with 5 fraction SBRT, the average maximum esophagus dose
with VMAT plans was 22.5 Gy, which equates to a biological effec-
tive dose (BED) of 56.3 Gy using an alpha/beta ratio of 3 for late
toxicity. The average D5 cc was 17.6 Gy, which has a BED of
38.3 Gy. These were similar to the maximum and D5 cc doses on
the single fraction study, which were 53.0 and 36.7 Gy BED, respec-
tively. However, the BED of the maximum and D5 cc doses for the
hybrid plans on the current study were much higher at 75.6 and
52.3 Gy, respectively. Our results suggest that fractionated VMAT
plans offer significantly reduced esophageal toxicity compared to
hybrid plans. Effective doses to the esophagus are similar compared
to single fraction plans but come with the benefit of a wider thera-
peutic ratio conferred by delivering the dose over multiple fractions.
Treatment time is another major clinical consideration in the
delivery of spinal SBRT. Beam-on times for single fraction radio-
surgery to spinal lesions have been reported for various modalities in
a recent study by Nalichowski et al., ranging from as low as 4.4 min
with flattening filter free (FFF) RapidArc to 58.1 min with Cyber-
Knife.36 The authors reported that CyberKnife was the only modality
that used noncoplanar beams and produced the lowest spinal cord
doses and best conformality; however, these benefits came at the
cost of much longer treatment times. In our study, we found that
VMAT allowed for faster delivery of radiation compared to non-
coplanar hybrid plans while actually improving conformality and
normal tissue sparing. The average beam-on time was 4.7 min for
VMAT compared 7.1 min for hybrid plans (not accounting for couch
kicks). In actuality, effective treatment times for hybrid plans using
noncoplanar arcs are much longer due to required repositioning of
the table (couch kicks) by the therapist during treatment. For the
patient population with spinal metastases undergoing palliative radia-
tion, prolonged treatment times can cause significantly more pain
and discomfort, which can also result in additional patient movement
and aborted treatments. Our results demonstrate that VMAT allows
for faster treatments through the use of coplanar arcs without sacri-
ficing target coverage and OAR sparing.
Wu et al. have previously reported a series of 10 patients trea-
ted with SBRT to the spine using either static IMRT or VMAT plans
(with one or two arcs). When only one arc was used, VMAT plans
were significantly worse in terms of spinal cord dosing, but there
was no difference with two arcs. The mean treatment times were
improved with VMAT plans (6.38 min beam-on time for 2 arc plans).
In our study, we used three coplanar arcs for VMAT plans, and
found similarly improved treatment efficiency without any significant
difference in spinal cord sparing.37
5 | CONCLUSION
In this paper, we have presented the results of our study investigat-
ing the feasibility of using VMAT for SBRT spine treatments instead
of noncoplanar hybrid arcs. VMAT plans resulted in improved dose
distributions and normal tissue sparing compared to NCHA plans.
Treatment times were significantly shorter with VMAT plans, which
is advantageous in both clinical efficiency as well as minimizing
patient discomfort and intrafraction movement error. VMAT planning
using SBRT is an attractive option for the treatment of metastases
to thoracic vertebrae, and further investigations using alternative
fractionation schedules are warranted.
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